Literature DB >> 23250544

Effects of smoking in patients treated with cardiac resynchronization therapy.

Laura Perrotta1, Brunilda Xhaferi, Marco Chiostri, Paolo Pieragnoli, Giuseppe Ricciardi, Luigi Di Biase, Andrea Natale, Ilaria Ricceri, Mazda Biria, Dhanunjay Lakkireddy, Alessandro Valleggi, Michele Emdin, Federica Michelotti, Giosuè Mascioli, Angela Pandozi, Massimo Santini, Luigi Padeletti.   

Abstract

Smoking is associated with increased morbidity and mortality in cardiac patients. However, data on the prognostic impact of smoking in heart failure (HF) patients on cardiac resynchronization therapy with defibrillator (CRT-D) are absent. We investigated the effects of smoking on all-cause mortality and on a composite endpoint (all-cause death/appropriate device therapy), appropriate and inappropriate device therapy, in 649 patients with HF who underwent CRT-D between January 2003 and October 2011 in 6 Centers (4 in Italy and 2 in USA). 68 patients were current smokers, 396 previous-smokers (patients who had smoked in the past but who had quit before the CRT-D implant), and 185 had never smoked. The risk of each endpoint by smoking status was evaluated with both Kaplan-Meier and Cox proportional-hazard analysis. After adjusting for age, left ventricular ejection fraction, QRS width and ischemic etiology, both current and previous smoking were independent predictors of all-cause death [HR = 5.07 (95 % CI 2.68-9.58), p < 0.001 and HR = 2.43 (95 % CI 1.38-4.29), p = 0.002, respectively) and of composite endpoint [HR = 1.63 (1.04-2.56); p = 0.033 and HR = 1.46 (1.04-2.04) p = 0.027]. In addition, current smokers had a significantly higher rate of inappropriate device therapy compared to never smokers [HR = 21.74 (4.53-104.25), p = 0.005]. Our study indicates that in patients with HF who received a CRT-D device, current and previous smoking increase the event rate per person-time of death and of appropriate and inappropriate ICD therapy more than other known negative prognostic factors such as age, left ventricular dysfunction, prolonged QRS duration and ischemic etiology.

Entities:  

Mesh:

Year:  2012        PMID: 23250544     DOI: 10.1007/s11739-012-0891-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  45 in total

1.  Cardiac-resynchronization therapy for mild-to-moderate heart failure.

Authors:  Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators.

Authors:  Ilan Goldenberg; Arthur J Moss; Scott McNitt; Wojciech Zareba; James P Daubert; W Jackson Hall; Mark L Andrews
Journal:  J Cardiovasc Electrophysiol       Date:  2006-06-06

3.  Smokers are at markedly increased risk of appropriate defibrillator shocks in a primary prevention population.

Authors:  José Mauricio Sánchez; Scott L Greenberg; Jane Chen; Marye J Gleva; Bruce D Lindsay; Timothy W Smith; Mitchell N Faddis
Journal:  Heart Rhythm       Date:  2006-04       Impact factor: 6.343

4.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B DeLurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; JoAnn Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano; Inder Anand; Carina Blomström-Lundqvist; John P Boehmer; Hugh Calkins; Serge Cazeau; Victoria Delgado; N A Mark Estes; David Haines; Fred Kusumoto; Paco Leyva; Frank Ruschitzka; Lynne Warner Stevenson; Christian Tobias Torp-Pedersen
Journal:  Europace       Date:  2012-09       Impact factor: 5.214

Review 5.  Myocardial potassium loss and cell depolarisation in ischaemia and hypoxia.

Authors:  A A Wilde; G Aksnes
Journal:  Cardiovasc Res       Date:  1995-01       Impact factor: 10.787

6.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.

Authors:  J He; L G Ogden; L A Bazzano; S Vupputuri; C Loria; P K Whelton
Journal:  Arch Intern Med       Date:  2001-04-09

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk? Results from a computer model tested through monte carlo simulations.

Authors:  Renato P Ricci; Loredana Morichelli; Alessio Gargaro; Maria T Laudadio; Massimo Santini
Journal:  J Cardiovasc Electrophysiol       Date:  2009-07-13

9.  Atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial.

Authors:  Luigi Padeletti; Carmine Muto; Themistoclis Maounis; Andreas Schuchert; Maria-Grazia Bongiorni; Robert Frank; Thomas Vesterlund; Johannes Brachmann; Alfredo Vicentini; Gaël Jauvert; Giorgio Tadeo; Daniel Gras; Francesco Lisi; Antonio Dello Russo; Jean-Luc Rey; Eric Boulogne; Giuseppe Ricciardi
Journal:  Am Heart J       Date:  2008-07-07       Impact factor: 4.749

10.  Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study.

Authors:  Jan Heeringa; Jan A Kors; Albert Hofman; Frank J A van Rooij; Jacqueline C M Witteman
Journal:  Am Heart J       Date:  2008-10-14       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.